Bone Therapeutics « Terug naar discussie overzicht

Bone 2021

197 Posts, Pagina: 1 2 3 4 5 6 7 8 9 10 » | Laatste
natje1966
1
Voor iedereen een gelukkig en vooral gezond 2021
Hopelijk dit jaar een doorbraak voor Bone
Ze zijn in ieder geval heel goed bezig
Phill
0
Bedankt natje, na lang wachten hopelijk de mogelijke doorbraak dit jaar.
Ik kijk er in ieder geval naar uit :-)
Ivel
0
Het kan wel eens rap gaan in 21'.
Bone wordt gewaardeerd op amper 45m €, bij positieve testresultaten van JTA-004 zal dat serieus opgevezen worden. En wie weet welke partnerships er nog aangegaan worden, Bone gaf eerder al aan dat dat prioritair is momenteel. Het belooft spannend te worden ;)
Edwin71
0
Vanaf wanneer mogen de aandelen van de kapitaalsverhoging verkocht worden? Wat toch van belang is want die zitten nu op korte termijn met een behoorlijke winst van 2.25 naar 2.70!
Ivel
0
quote:

Edwin71 schreef op 7 januari 2021 11:57:


Vanaf wanneer mogen de aandelen van de kapitaalsverhoging verkocht worden? Wat toch van belang is want die zitten nu op korte termijn met een behoorlijke winst van 2.25 naar 2.70!

Er was een lock-up van 180 dagen vastgelegd.
natje1966
1
bone goed bezig , op naar hogere rangen
misschien wel partnerships
en als we nog een tijdje groen blijven kunnen we misschien wal naar een 4
natje1966
0
Bassie152
0
Bone Therapeutics : 1/12/21 - Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
01/12/2021 | 01:06am EST
share with twitter
share with LinkedIn
share with facebook
Gosselies, Belgium, 12 January 2021, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures.
The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study, the potential of ALLOB to accelerate fracture healing and prevent late-stage complications in patients with difficult fractures in the shinbone (tibia), will be evaluated and compared to placebo, on top of standard of care after a follow-up period of 6 months. ALLOB will be applied by a single percutaneous injection 24-96 hours post reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union. The study has been approved in 7 European countries (Belgium, Czech Republic, France, Germany, Hungary, Poland and Spain). The study is expected to enroll 178 patients in over 40 sites. Bone Therapeutics anticipates finalizing patient recruitment in H1 2022. Topline results are expected in second half of 2022. Both events are subject to evolution of the COVID-19 pandemic and the associated containment measures.
'The start of the ALLOB clinical study in difficult tibial fractures is a critical step for Bone Therapeutics. Difficult fractures remain an underserved condition with limited therapeutic options, which can result in lifelong disability and amputations. There are estimated more than 1.7 million procedures in the EU5, US and Japan alone (1). A positive outcome of this study could lead to a valuable treatment for these patients at risk of delayed or non-union fractures.' said Miguel Forte, CEO, Bone Therapeutics. 'This Phase IIb first patient treatment for ALLOB follows positive 24-month results for the Phase IIa ALLOB clinical trial in lumbar spinal fusion procedures, as well as our completion of the recruitment and patient treatment of the pivotal Phase III clinical study with the improved viscosupplement, JTA-004, in patients with knee osteoarthritis. The successful completion of Bone Therapeutics' ALLOB trials would further demonstrate the promise of mesenchymal stromal derived cell therapies for the treatment of other underserved conditions.'
About ALLOB and Bone Therapeutics' proprietary, scalable cell therapy manufacturing process
ALLOB is Bone Therapeutics' off-the-shelf allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. To address critical factors for the development and commercialization of cell therapy products, Bone Therapeutics has established a proprietary, optimized production process that improves consistency, scalability, cost effectiveness and ease of use of ALLOB. This optimized production process significantly increases the production yield, generating thousands of doses per bone marrow donation. Additionally, the final ALLOB product is cryopreserved, enabling easy shipment and the capability to be stored at the point of care for easy clinical use. The process will therefore substantially improve product quality, reduce overall production costs, simplify supply chain logistics, increase patient accessibility and facilitate global commercialization. The Company has implemented the optimized production process to produce clinical batches for the ongoing Phase IIb clinical trial in patients with difficult-to-heal tibial fractures.
(1) Bone Therapeutics' estimates.



1 dag te laat maar hier nog niet gedeeld.
Bassie152
0
Bij deze het partnership waar ze een tijd geleden al over spraken. Gericht op, onder andere, het stroomlijnen van de nog goed te keuren medicijnen JTA-004 en ALLOB. Een bedrijf met een visie of op basis van interne kennis vooruit lopen op de muziek? Beide zijn in mijn optiek als positief te beschouwen.

01/14 BONE THERAPEUTICS : Signs Process Development Partnership With Rigenerand
MT
01/14 BONE THERAPEUTICS : 1/14/21 - Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
PU
01/14 BONE THERAPEUTICS : and Rigenerand sign partnership for cell therapy process development
AQ
Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions
Summary Most relevant All News Press Releases Official Publications Sector news
Bone Therapeutics : 1/14/21 - Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
01/14/2021 | 01:06am EST
share with twitter
share with LinkedIn
share with facebook
Gosselies, Belgium and Modena, Italy, 14 January 2021, 7am CET - BONE THERAPEUTICS (
Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, the biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, today announce the signing of a first agreement for a process development partnership. 'Allogeneic mesenchymal stem cell (MSC) therapies are currently being developed at an incredible pace and are evaluated in numerous clinical studies covering diverse therapeutic areas such as bone and cartilage conditions, liver, cardiovascular and autoimmune diseases in which MSCs could have a significant positive effect. Advances in process development to scale up these therapies could have major impacts for both their approval and commercial viability. This will be essential to bring these therapies to market to benefit patients as quickly as possible,' said Miguel Forte, CEO, Bone Therapeutics. 'Hence, whilst Bone Therapeutics is driving on its existing clinical development programs, we have signed a first formal agreement with Rigenerand as a fellow MSC-based organization. This will result in both companies sharing extensive expertise in the process development and manufacturing of MSCs and cell and gene therapy medicinal products. Bone Therapeutics also selected Rigenerand to partner with for their additional experience with wider process development of advanced therapy medicinal products (ATMPs), including the conditioning and editing of MSCs. Rigenerand was founded by Massimo Dominici, a world opinion leader in the cell therapy with an unparalleled MSC expertise and knowledge.' The scope of collaborations between Bone Therapeutics and Rigenerand aims to focus on different aspects of product and process development for Bone Therapeutics' expanding therapeutic portfolio. Rigenerand will contribute to improving the processes involved in the development and manufacture of Bone Therapeutics' MSC based allogeneic differentiated cell therapy products as they advance towards patients. The first collaboration between the two organizations will initially focus on augmented professional bone-forming cells - cells that are differentiated and programmed for a specific task. There is also potential for Bone Therapeutics to broaden its therapeutic targets and explore new mechanisms of action with potential gene modifications for its therapeutic portfolio. In addition to Rigenerand's MSC expertise, Bone Therapeutics also selected Rigenerand as a partner for Rigenerand's GMP manufacturing facility. This facility, situated in Modena, Italy, has been designed to host a number of types of development processes for ATMPs. These include somatic, tissue engineered and gene therapy processes. These multiple areas of Rigenerand capabilities enable critical development of new processes and implementation of the gene modification of existing processes. In addition, Rigenerand has built considerable experience in cGMP manufacturing of MSC-based medicinal products, including those that are genetically modified. 'Process development and manufacturing is a key part of the development for ATMPs internationally. Navigating these therapies through the clinical development phase and into the market requires a carefully considered process development pathway,' said Massimo Dominici, scientific founder, Rigenerand, professor of medical oncology, and former President of the International Society for Cell & Gene Therapy (ISCT). 'This pathway needs to be flexible, as both the market and materials of these therapies continues to evolve alongside an improved clinical efficacy.' 'Rigenerand will offer considerable input from its experience of MSC-based therapies to enable Bone Therapeutics to keep and further accelerate the pace in development of the product processes of its MSC based allogeneic differentiated cell therapy as they advance towards patients,' said Giorgio Mari, CEO, Rigenerand. 'We will continue to use our MSC expertise in the development of Rigenerand's own products, as well as in process development and manufacturing cell and gene therapies for partner organizations across the globe.'
psps
0
Koopadvies op Bone vanmorgen, koersdoel Kepler € 5,20. Maar even wat aandelen zo wegsnoepen op € 2,87.
belegger1981
0
Ivel
0
quote:

belegger1981 schreef op 24 januari 2021 20:26:


Goeieavond,
Is het interessant om aan die prijs (2,87€)nu nog aan te kopen?
Mvg

Het bedrijf wordt enorm laag gewaardeerd door de markt.
Indien er positieve resultaten komen in het 3e kwartaal zal daar een grote verandering in komen.
belegger1981
0
quote:

Ivel schreef op 25 januari 2021 11:07:


[...]
Het bedrijf wordt enorm laag gewaardeerd door de markt.
Indien er positieve resultaten komen in het 3e kwartaal zal daar een grote verandering in komen.


Bedankt alvast
Diedelien
0
belegger1981, als je nu niet aankoopt dan moet je het nooit meer doen. Nog altijd heel optimistisch, maar altijd bekijken op de LT.
belegger1981
0
quote:

Diedelien schreef op 25 januari 2021 17:39:


belegger1981, als je nu niet aankoopt dan moet je het nooit meer doen. Nog altijd heel optimistisch, maar altijd bekijken op de LT.


Ik stap wellicht morgen in,ik las dat dit jaar van belang is voor een goedkeuring?
Klopt dit?
Hoe ziet u de koers verder evolueren?
Vandaag toch redelijk in het rood daarom heb ik vandaag nog niet aangekocht..
Alvast bedankt
197 Posts, Pagina: 1 2 3 4 5 6 7 8 9 10 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 15 okt 2021 17:35
Koers 1,414
Verschil -0,034 (-2,35%)
Hoog 1,442
Laag 1,400
Volume 14.819
Volume gemiddeld 77.438
Volume gisteren 20.115